

AGENDA

Uniform Formulary Beneficiary Advisory Panel 19 September 2013 @ 0900 AM

*Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004*

- **Administrative Meeting (BAP members only @ 7:30 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drug classes during the August 2013 meeting:

- *Drug Class Reviews:*
 - *Corticosteroid Immune Modulators (Topical Steroids)*
 - *Self-Monitoring Blood Glucose System (SMBGS) Test Strips*
- *Utilization Management Issues*
 - *Prior Authorization Criteria*
 - *Injectable Corticotropin (HP Acthar Gel)*
 - *Doxylamine/Pyridoxine (Diclegis)*
 - *Targeted Immunomodulatory Biologics:*
 - *Ustekinumab (Stelara)*
 - *Golimumab (Simponi)*
- *2008 Section 703 Actions*
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the

recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.